GlassScriptPhysician profile
Rekha Babu Kumar
NPI 1598922023
$86,796.46
in general payments reported to CMS, 2019-2025
14 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $26K · 2021: $20K · 2022: $4,294 · 2023: $1,895 · 2024: $101 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,594 · Food and Beverage: $656 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,593.75 |
| Food and Beverage | $656.15 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $75,757.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $4,000.00 | 2022 | |
| Pfizer INC. | $3,800.00 | 2020 | |
| Novo Nordisk As | $2,397.78 | 2019-2021 | |
| Lilly USA, LLC | $377.79 | 2019-2024 | Mounjaro |
| Eli Lilly and Company | $139.36 | 2023 | |
| Sanofi-Aventis U.S. LLC | $108.15 | 2020 | |
| Mannkind Corporation | $101.90 | 2022-2025 | |
| Vivus LLC | $24.75 | 2019 | |
| Ibsa Pharma INC. | $21.75 | 2021 | |
| Amgen INC. | $21.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.84 | 2021 | |
| Currax Pharmaceuticals LLC | $14.14 | 2025 | Contrave |
| Boston Scientific Corporation | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.